FCR 002
Alternative Names: FCR-002Latest Information Update: 20 Oct 2023
Price :
$50 *
At a glance
- Originator Talaris Therapeutics
- Developer Tourmaline Bio
- Class Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Renal transplant rejection
Most Recent Events
- 19 Oct 2023 Talaris Therapeutics has merged with Tourmaline Bio to form Tourmaline Bio
- 14 Jun 2021 Talaris Therapeutics plans to file an IND application with the US FDA for Renal transplant rejection (Prevention) (from deceased donor)
- 14 Jun 2021 Talaris Therapeutics plans a clinical trial for Renal transplant rejection (Prevention) (from deceased donor) in USA